MNG266
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.645
- E2F_TARGETS+0.603
- MYC_TARGETS_V1+0.539
- G2M_CHECKPOINT+0.524
- DNA_REPAIR+0.351
- OXIDATIVE_PHOSPHORYLATION+0.304
- UNFOLDED_PROTEIN_RESPONSE+0.295
- MTORC1_SIGNALING+0.223
- MITOTIC_SPINDLE+0.211
- PI3K_AKT_MTOR_SIGNALING+0.059
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.377
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.362
- IL2_STAT5_SIGNALING-0.356
- COAGULATION-0.351
- ANGIOGENESIS-0.323
- PANCREAS_BETA_CELLS-0.315
- TNFA_SIGNALING_VIA_NFKB-0.313
- APICAL_SURFACE-0.312
- HYPOXIA-0.306
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.303
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12475130 | — | — | 0.898 |
| 2 | SRR15030859 | — | — | 0.891 |
| 3 | AUR-AG0N-TTM1-A-1-1-R-A743-41 | — | E | 0.887 |
| 4 | 2B4FA61A-C1A7-49BD-9438-2865D386EAF2 | — | — | 0.885 |
| 5 | BS_M4923M40 | ATRT | — | 0.881 |
| 6 | SAMN03290940 | — | — | 0.877 |
| 7 | 20030039.TNBC | — | E | 0.874 |
| 8 | TCGA-63-7023-01A-11R-1949-07 | — | cohortSQ2 | 0.874 |
| 9 | TCGA-21-1080-01A-01R-0692-07 | — | cohortSQ1 | 0.871 |
| 10 | SRR10900561 | — | — | 0.870 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.645 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.603 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.539 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.524 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.351 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.304 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.295 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.223 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.211 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.059 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.035 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.008 | Inavolisib | — uncovered |